ARYx to Present at the Oppenheimer & Co. 19th Annual Health Care Conference.FREMONT, Calif. -- ARYx Therapeutics, Inc. (NASDAQ NASDAQ in full National Association of Securities Dealers Automated Quotations U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on :ARYX) today announced that it will present at the Oppenheimer & Co. 19th Annual Health Care Conference in New York New York, state, United States New York, Middle Atlantic state of the United States. It is bordered by Vermont, Massachusetts, Connecticut, and the Atlantic Ocean (E), New Jersey and Pennsylvania (S), Lakes Erie and Ontario and the Canadian province of , NY. A live webcast of the presentation scheduled for Tuesday, November 4 at 2:40 p.m. Eastern Time may be accessed at the ARYx website http://www.aryx.com. The presentation will be archived for 90 days. About ARYx Therapeutics, Inc. ARYx Therapeutics is a biopharmaceutical company focused on developing a portfolio of internally discovered products designed to eliminate known safety issues associated with well-established, commercially successful drugs. ARYx uses its RetroMetabolic Drug Design technology to design structurally unique molecules that retain the efficacy of these original drugs but are metabolized through a potentially safer pathway to avoid specific adverse side effects Side effects Effects of a proposed project on other parts of the firm. associated with these compounds. ARYx currently has four products in clinical trials: an oral anticoagulant anticoagulant (ăn'tēkōăg`yələnt), any of several substances that inhibit blood clot formation (see blood clotting). agent for patients at risk for the formation of dangerous blood clots, ATI-5923; an oral anti-arrhythmic agent for the treatment of atrial fibrillation, ATI-2042; a prokinetic agent for the treatment of various gastrointestinal disorders, ATI-7505; and, an agent for the treatment of schizophrenia The concept of a cure as such in the treatment of schizophrenia remains controversial, as there is no consensus on the definition of "treatment" in the case of schizophrenia, although some criteria for the remission of symptoms have recently been suggested. and other psychiatric disorders, ATI-9242. Please visit our web site at www.aryx.com for additional information. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion